Patents by Inventor Bhaskar C. Das

Bhaskar C. Das has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
    Patent number: 11591324
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 28, 2023
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders
    Publication number: 20220071953
    Abstract: In an embodiment, the present disclosure pertains to compositions and methods for modulating cellular glucose uptake. In general, the methods include associating cells with the compositions of the present disclosure. In another aspect, the present disclosure pertains to compositions and methods to treat or prevent a disorder in a subject. The methods generally include administering the compositions of the present disclosure to the subject.
    Type: Application
    Filed: January 8, 2020
    Publication date: March 10, 2022
    Applicant: Texas Tech University System
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF
    Publication number: 20210053958
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Application
    Filed: August 4, 2020
    Publication date: February 25, 2021
    Inventors: Ana Maria CUERVO, Evripidis GAVATHIOTIS, Qisheng XIN, Bhaskar C. DAS
  • Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
    Patent number: 10766886
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 8, 2020
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF
    Publication number: 20190225599
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Application
    Filed: December 5, 2018
    Publication date: July 25, 2019
    Inventors: Ana Maria CUERVO, Evripidis GAVATHIOTIS, Qisheng XIN, Bhaskar C. DAS
  • Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
    Patent number: 10189827
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 29, 2019
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • Small molecule analogs of E4orf1
    Patent number: 10047107
    Abstract: The invention relates to amino nitrile compounds. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: August 14, 2018
    Assignee: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
    Inventors: Bhaskar C. Das, Nikhil V. Dhurandhar
  • RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF
    Publication number: 20180141937
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 24, 2018
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • Compositions and methods for improving glucose uptake
    Patent number: 9714259
    Abstract: A compound includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: July 25, 2017
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • COMPOSITIONS AND METHODS FOR IMPROVING GLUCOSE UPTAKE
    Publication number: 20170044189
    Abstract: A compound includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Application
    Filed: May 23, 2016
    Publication date: February 16, 2017
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTHOPHAGY MODULATORS AND USES THEREOF
    Publication number: 20170037039
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Applicant: Albert Einstein College of Medicine, Inc.
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • SMALL MOLECULE ANALOGS OF E4orf1
    Publication number: 20170037064
    Abstract: The invention relates to amino nitrile compounds. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 9, 2017
    Inventors: Bhaskar C. DAS, Nikhil V. DHURANDHAR
  • Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
    Patent number: 9512092
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: December 6, 2016
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • Compositions and methods for improving glucose uptake
    Patent number: 9469659
    Abstract: A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound that includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: October 18, 2016
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • Compositions and methods for improving glucose uptake
    Patent number: 9346835
    Abstract: A compound includes the structure of general Formula (II), pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: May 24, 2016
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • COMPOSITIONS AND METHODS FOR IMPROVING GLUCOSE UPTAKE
    Publication number: 20160113951
    Abstract: A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound that includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Application
    Filed: January 7, 2016
    Publication date: April 28, 2016
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • COMPOSITIONS AND METHODS FOR IMPROVING GLUCOSE UPTAKE
    Publication number: 20150266903
    Abstract: A compound includes the structure of general Formula (II), pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 24, 2015
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF
    Publication number: 20150166492
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Application
    Filed: December 11, 2014
    Publication date: June 18, 2015
    Inventors: ANA MARIA CUERVO, EVRIPIDIS GAVATHIOTIS, QISHENG XIN, BHASKAR C. DAS
  • Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
    Patent number: 8669260
    Abstract: The application discloses ketoconazole derivatives that are antagonists of the human pregnane X receptor (PXR), methods of preparing the derivatives, uses of the derivatives with drug therapy, and methods of inhibiting tumor cell proliferation and multidrug resistance using inhibitors of PXR.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: March 11, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Sridhar Mani, Bhaskar C. Das
  • NOVEL LIPOGENIC INHIBITORS AND USES THEREOF
    Publication number: 20140051661
    Abstract: The present invention provides resveratrol-based boron-containing analog! methods of use thereof in treatment of dyslipidemias and cancer.
    Type: Application
    Filed: February 15, 2012
    Publication date: February 20, 2014
    Applicants: The Texas A&M University System, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Bhaskar C. Das, Fajun Yang, Xiaoping Zhao, Jeffrey E. Pessin, Haihong Zong, Jun-Yuan Ji